Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Charrow

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
American Journal of Medical Genetics. Part A|April 9, 2020
Oligosaccharyltransferase complex-congenital disorders of glycosylation: A novel congenital disorder of glycosylationEmily M Bryant, John J Millichap, Egidio Spinelli, et al.
European Journal of Pediatrics|December 17, 2003
Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statementsGregory A Grabowski, Generoso Andria, Antonio Baldellou, et al.
European Journal of Pediatrics|December 17, 2003
Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoringAntonio Baldellou, Generoso Andria, Pauline E Campbell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski, Katherine Kacena, J Alexander Cole, et al.
American Journal of Hematology|April 30, 2024
Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher RegistryPramod K Mistry, Manisha Balwani, Joel Charrow, et al.
Cold Spring Harbor Molecular Case Studies|February 20, 2021
Transcript analysis for variant classification resolution in a child with primary ciliary dyskinesiaAlexander Ing, Alissa Wlodaver, Dawn Kirschmann, et al.
Molecular Genetics and Metabolism|June 6, 2015
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imigluceraseLaurie Smith, William Rhead, Joel Charrow, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.
Molecular Genetics and Metabolism|August 12, 2016
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry RegistryRobert J Hopkin, Gustavo Cabrera, Joel Charrow, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
American Journal of Medical Genetics. Part A|April 9, 2020
Oligosaccharyltransferase complex-congenital disorders of glycosylation: A novel congenital disorder of glycosylationEmily M Bryant, John J Millichap, Egidio Spinelli, et al.
European Journal of Pediatrics|December 17, 2003
Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statementsGregory A Grabowski, Generoso Andria, Antonio Baldellou, et al.
European Journal of Pediatrics|December 17, 2003
Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoringAntonio Baldellou, Generoso Andria, Pauline E Campbell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski, Katherine Kacena, J Alexander Cole, et al.
American Journal of Hematology|April 30, 2024
Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher RegistryPramod K Mistry, Manisha Balwani, Joel Charrow, et al.
Cold Spring Harbor Molecular Case Studies|February 20, 2021
Transcript analysis for variant classification resolution in a child with primary ciliary dyskinesiaAlexander Ing, Alissa Wlodaver, Dawn Kirschmann, et al.
Molecular Genetics and Metabolism|June 6, 2015
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imigluceraseLaurie Smith, William Rhead, Joel Charrow, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.
Molecular Genetics and Metabolism|August 12, 2016
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry RegistryRobert J Hopkin, Gustavo Cabrera, Joel Charrow, et al.
Pageof 11